Active substance

Results for the substance pemigatinib

4 results

About this active substance

Pemigatinib is a medication used for the treatment of certain types of cancer, such as cholangiocarcinoma (bile duct cancer) with fibroblast growth factor receptor (FGFR) mutations. It acts as an FGFR inhibitor, blocking abnormal cellular signaling and slowing tumor growth.

The medication is taken orally, usually in tablet form, and should be used as directed by your doctor. Regular check-ups are important to monitor the effectiveness of the treatment and any potential side effects.

Side effects may include fatigue, nausea, diarrhea, dry mouth, or electrolyte imbalances. In rare cases, severe adverse effects such as liver or eye function impairment may occur, requiring immediate medical attention.

Patients should inform their doctor about any other medications being used or pre-existing conditions to ensure the safe use of pemigatinib.